14-3-3 eta depletion sensitizes glioblastoma cells to irradiation due to enhanced mitotic cell death
Authors:
Open Access
- 14 March 2014
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 21 (4) , 158-163
Abstract
14-3-3 proteins have important roles in several cellular processes such as cell cycle progression, the DNA-damage checkpoint and apoptosis. We have shown previously that depleting 14-3-3η, a 14-3-3 isoform, enhances mitotic cell death, and that combining it with microtubule agents is more effective for anticancer therapeutics. In this study, we investigated whether depleting 14-3-3η can be combined with radiotherapy to enhance its therapeutic efficacy. We found that depleting 14-3-3η resulted in a synergistic radiosensitizing effect when combined with radiotherapy in several glioblastoma cell lines, where its specific expression and correlation of its expression level with malignancy have been reported. The radiosensitizing effect was associated with enhanced mitotic cell death by 14-3-3η depletion but not with mitotic catastrophe, which is one of the major cell death mechanisms observed in response to irradiation of most solid tumors. These results suggest that 14-3-3η may be a therapeutic target to overcome radioresistance in glioblastoma.Keywords
This publication has 18 references indexed in Scilit:
- Roles of 14-3-3η in mitotic progression and its potential use as a therapeutic target for cancersOncogene, 2012
- Understanding the limitations of radiation-induced cell cycle checkpointsCritical Reviews in Biochemistry and Molecular Biology, 2011
- Molecular therapy in support to radiotherapyMutation Research - Reviews in Mutation Research, 2010
- Radiation-induced cell death mechanismsTumor Biology, 2010
- Mitotic catastrophe is the predominant response to histone acetyltransferase depletionCell Death & Differentiation, 2008
- G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancerBritish Journal of Cancer, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- 14-3-3 proteins: A historic overviewSeminars in Cancer Biology, 2006
- Control of oncogenesis and cancer therapy resistanceBritish Journal of Cancer, 2004
- How do 14‐3‐3 proteins work? – Gatekeeper phosphorylation and the molecular anvil hypothesisFEBS Letters, 2001